China’s I-Mab Biopharma completed a $220 million Series C round led by Hony Capital. It was, according to the company, one of the largest C rounds ever for an innovative China biotech. I-Mab was formed in early 2017 when C-Bridge Capital and Tasly Pharma merged two China entities, Third Venture Biotech and Tasgen Bio, and invested $150 million in the consolidated company. At the time, I-Mab was said to have twelve antibody drug candidates.
Source: China Biotoday
